Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis

Table 2

Survival outcomes according to the systemic inflammation response index (SIRI) status and SIRI subgroups.

Outcome	SIRI < 1.9 (N = 304)	SIRI ≥ 1.9 (N = 304)	value	SIRI-1 (N = 171)	SIRI-2 (N = 345)	SIRI-3 (N = 92)	value
PFS
Median, mo	14.2 (12.8–15.6)	9.0 (8.4–9.6)	<0.001	15.0 (13.2–16.8)	11.1 (10.2–12.0)	7.1 (6.3–7.9)	<0.001
5 years (%)	7.4	16.0		19.8	9.8	0
10 years (%)	3.1	10.8		14.9	NR	0
OS
Median, mo	30.3 (27.8–32.8)	21.3 (19.5–23.1)	<0.001	36.7 (30.6–42.8)	23.9 (22.3–25.5)	13.8 (12.2–15.4)	<0.001
5 years (%)	12.3	30.5		31.4	19.3	0
10 years (%)	5.1	22.4		24.4	5.9	0

Bonferoni corrected P value <0.017 for significance. Note. SIRI-1: stage IIIB and SIRI < 1.9; SIRI-2: stage IIIB and SIRI ≥ 1.9 or stage IIIC and SIRI < 1.9; SIRI-3: stage IIIC and SIRI ≥ 1.9. Abbreviations. SIRI: systemic inflammation response index; PFS: progression-free survival; OS: overall survival.